+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study

Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study

Drugs and Aging 30(5): 321-330

The serum anticholinergic activity (SAA) assay has been used to quantify patients' anticholinergic load. In addition, several ranked lists of anticholinergic drugs have been developed to assess anticholinergic drug burden. This study investigated whether SAA assay results and scores from three ranked lists of anticholinergic drugs (Carnahan's Anticholinergic Drug Scale, Rudolph's Anticholinergic Risk Scale, and Chew's list) are associated with anticholinergic adverse drug events (ADEs) in older people. We analyzed data from participants in the population-based Geriatric Multidisciplinary Good Care of the Elderly Study in Kuopio, Finland (n = 621). Demographic, diagnostic, and drug use data were collected during standardized interviews and verified from medical records. Vision, functional capacity, cognition, and mood were assessed using validated techniques. The SAA was measured from blood samples. The SAA was not associated with anticholinergic ADEs. Anticholinergic drug burden computed using each of the three lists was inversely associated with short-distance vision (p < 0.01), activities of daily living (p < 0.05), and instrumental activities of daily living (p < 0.05) in persons with and without dementia. Furthermore, poorer Mini Mental State Examination and poorer Geriatric Depression Scale scores were associated with the anticholinergic drug burden in persons without dementia (p < 0.05-p < 0.001). The association between anticholinergic drug burden and ADEs was strongest when using the lists developed by Carnahan and Chew. Scores obtained from ranked lists of anticholinergic drugs were associated with clinically significant anticholinergic ADEs but the SAA was not. This finding supports the usefulness of these lists to help identify patients at risk of anticholinergic ADEs in clinical practice.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036802198

Download citation: RISBibTeXText

PMID: 23475596

DOI: 10.1007/s40266-013-0063-2

Related references

Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study. Drugs and Aging 30(11): 927-934, 2014

Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. American Journal of Geriatric PharmacoTherapy 4(1): 42-51, 2006

The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. Journal of Clinical Pharmacology 46(12): 1481-1486, 2006

Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures. American Journal of Geriatric Psychiatry 21(8): 785-793, 2014

Anticholinergic Risk and Frequency of Anticholinergic Drug Prescriptions in a Population Older Than 65. Journal of the American Medical Directors Association 17(3): 275.E1-4, 2016

Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. Journal of Clinical Pharmacology 49(10): 1176-1184, 2009

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. Bmc Geriatrics 15: 31, 2016

A systematic review and meta-analysis on serum anticholinergic activity and adverse outcomes in older people. Research in Social and Administrative Pharmacy 12(5): E35-E36, 2016

Audit of anticholinergic medication changes in older hospitalised patients using the Anticholinergic Drug Scale. Internal Medicine Journal 47(6): 689-694, 2017

Serum Anticholinergic Activity and Cognitive and Functional Adverse Outcomes in Older People: A Systematic Review and Meta-Analysis of the Literature. Plos One 11(3): E0151084, 2016

Limitations of the Anticholinergic Activity Assay and Assay-Based Anticholinergic Drug Scales. American Journal of Geriatric Psychiatry 24(12): 1182-1188, 2016

Anticholinergic drug burden in older people's brain - how well is it measured?. Basic and Clinical Pharmacology and Toxicology 114(2): 151-159, 2014

The anticholinergic risk scale and anticholinergic adverse effects in older persons. Archives of Internal Medicine 168(5): 508-513, 2008

Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines' levels of anticholinergic activity and clinical indications. Journal of Clinical Pharmacy and Therapeutics 41(5): 486-492, 2017

Anticholinergic and sedative drug burden in community-dwelling older people: a national database study. BMJ Open 8(7): E022500, 2018